Opiant Pharmaceuticals Gets US Patent Allowance for OPNT004 to Treat Cannabinoid Hyperemesis Syndrome
Opiant Pharmaceuticals Gets US Patent Allowance for OPNT004 to Treat Cannabinoid Hyperemesis Syndrome
Opiant制药公司获得OPNT004治疗大麻素性呕吐综合征的美国专利许可
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册